 SARASOTA, Fla., Oct. 1, 2021 PRNewswire -- INVO Bioscience, Inc. NASDAQ: INVO, a medical device company focused on commercializing the worlds only in vivo culture system IVC, INVOcell, today announced that it has entered into definitive agreements with institutional and accredited investors and members of INVO Biosciences management team to purchase 1,240,763 shares of its common stock at a purchase price of 3.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately 4.0 million. 